Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy plus sintilimab followed by furmonertinib for first-line EGFR-mutant advanced NSCLC
ChiCTR2500095781Phase 2Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and furmonertinib in non-small cell lung cancer (NSCLC), sponsored by The Second Xiangya Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
sintilimabfurmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500095781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095781.